Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling

At least 0.5% of people in the Western world develop inflammatory bowel disease (IBD). While antibodies that block tumor necrosis factor (TNF) α and Interleukin (IL-)23 have been approved for the treatment of IBD, IL-6 antibodies failed in the phase II clinical trial due to non-tolerable side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Gesiorowski, Annika, Ettich, Julia, Werner, Julia, Wittich, Christoph, Pieper, Stephan, Padrini, Giacomo, Behnke, Kristina, Floss, Doreen M., Lang, Philipp A., Moll, Jens M., Scheller, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652096/
https://www.ncbi.nlm.nih.gov/pubmed/37838173
http://dx.doi.org/10.1016/j.jbc.2023.105343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652096/
https://www.ncbi.nlm.nih.gov/pubmed/37838173
http://dx.doi.org/10.1016/j.jbc.2023.105343

Ejemplares similares